Are Benefits of Early Ezetimibe Conferred by its Effect on LDL-C? [0.03%]
早期使用依泽替米贝的益处是由其对LDL-C的作用带来的吗？
Anshul Yadav,Neelesh Gupta,Rajeev Gupta
Anshul Yadav
Reply: Teleprehabilitation Before Cardiac Surgery: Are There Benefits or Biases in Current Metrics? [0.03%]
回复：心脏手术前的远程康复：当前指标有哪些益处或偏倚？
Bart Scheenstra,Lieke van Susante,Peyman Sardari Nia
Bart Scheenstra
Reducing Cardiovascular Events With Early Ezetimibe: Getting to "Europe on Target" From "Jena auf Ziel" [0.03%]
早期使用依折麦布降低心血管事件的发生：“从‘Jena Auf Ziel’到‘欧洲达标’”
Franz Haertel,P Christian Schulze,Harry R Davis et al.
Franz Haertel et al.
Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage: A Meta-Analysis of Randomized Trials [0.03%]
颅内出血幸存者的房颤抗凝治疗：随机对照试验的meta分析研究
Kuan-Yu Chi,Yu Chang,Pei-Lun Lee et al.
Kuan-Yu Chi et al.
Misclassification of Myocardial Infarction Subtypes in Administrative Claims: Implications for Clinical Epidemiology and Quality Assessment [0.03%]
急性心肌梗死亚型在行政保险索赔数据库中的误分类及其临床流行病学和医疗质量评估意义
Andrea Martinez,Muhammad Etiwy,James L Januzzi Jr et al.
Andrea Martinez et al.
Outcomes in Older Patients Undergoing Surgical Aortic Valve Replacement With Concomitant Procedures [0.03%]
合并其他手术的人工主动脉瓣置换术的远期效果：老年患者的预后分析
Harun Kundi,Jeffrey J Popma,Juan F Granada et al.
Harun Kundi et al.
Private Equity in Heart Failure Care: Where Chronic Disease and Acute Financial Pressures Collide [0.03%]
私募股权进军心力衰竭护理领域：慢性病与急性财务压力的碰撞
Karen E Joynt Maddox,Patrick Aguilar
Karen E Joynt Maddox
Body Mass Index, Central Adiposity, and HFpEF: Some Answers But More Questions [0.03%]
体质指数、中心型肥胖与HFpEF：已有的答案和未解的问题
Klara R Klein,Jaime P Almandoz,Darren K McGuire et al.
Klara R Klein et al.
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial [0.03%]
体重指数、中心性肥胖、体重减轻对心衰患者经 Tirzepatide 治疗的获益影响：SUMMIT试验
Barry A Borlaug,Michael R Zile,Christopher M Kramer et al.
Barry A Borlaug et al.
Background: The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist tirzepatide decreased the risk of cardiovascular death or worseni...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Jul 29;86(4):242-255. DOI:10.1016/j.jacc.2025.04.059 2025